Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Wellstat Therapeutics Corporation (rights to uridine triacetate)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Distribution rights in the United States of uridine triacetate drug. The drug is used for treating patients at risk of serious toxicity following an overdose of 5-flourouracil.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Acquirer
Primary Office
  • 930 Clopper Road
  • Gaithersburg, MD 20878
  • United States

Wellstat Therapeutics Corporation (rights to uridine triacetate) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.

Request full access to PitchBook

Wellstat Therapeutics Corporation (rights to uridine triacetate) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Wellstat Therapeutics Corporation (rights to uridine triacetate)‘s full profile, request access.

Request full access to PitchBook